Metagenomi Q3: $101.7M Cash, Loss Narrows to $21.1M, $7.5M Securities Settlement
MGX sits 20% above its 52-week low of $0.6.
Summary
Metagenomi's Q3 10-Q details the $101.7 million cash position behind today's IND-clearance announcement, with R&D cuts and lower burn offsetting a collapse in collaboration revenue to $3.2 million for nine months. It also discloses a $7.5 million settlement in principle of the securities class action, $6.3 million of it insured.
Key Events · Earnings and Guidance · MGX
-
Q3 Loss Narrows on Cost Cuts
Net loss was $21.1 million, or $0.56 per share, versus $20.4 million ($0.55) a year earlier. R&D fell to $17.5 million from $25.3 million, while G&A rose to $6.9 million on a $1.2 million net litigation charge.
-
Cash of $101.7M Funds Operations Into 2028
Cash, equivalents and available-for-sale securities were $101.7 million at September 30, 2026, down from $160.8 million at December 31, 2025. Nine-month operating cash burn was $59.8 million versus $65.3 million a year earlier.
-
Collaboration Revenue Collapses
Nine-month collaboration revenue fell to $3.2 million from $21.3 million a year earlier, including a $2.6 million cumulative catch-up reduction from the April 1, 2026 Ionis agreement modification.
-
Securities Class Action Settled for $7.5M
The parties reached an agreement in principle on October 21, 2026 to settle the Section 11/15 class action for $7.5 million, subject to court approval, with $6.3 million funded by insurance and a $1.2 million net charge to G&A.
Analysis · MGX · Life Sciences
The headline news—FDA clearance of the MGX-001 hemophilia A IND and $101.7 million in cash to fund operations into 2028—already broke this morning via 8-K and press release. The 10-Q's real contribution is showing the quality of that runway. R&D fell to $17.5 million from $25.3 million a year earlier, and nine-month operating cash burn dropped to $59.8 million from $65.3 million; that is what actually stretches the cash into 2028. Against that, collaboration revenue collapsed to $3.2 million for nine months from $21.3 million, leaving the company almost entirely dependent on its own programs and future financings. The other new item is the securities class action, settled in principle for $7.5 million with $6.3 million covered by insurance, leaving a $1.2 million net hit to G&A—a contained resolution of an overhang dating to the 2024 IPO. With $75.0 million of ATM capacity unused and the Baby Shelf Rule capping how much can be raised, dilution risk remains the main constraint on the stock.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGX was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $0.60 to $2.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.